Semax Research

Dolotov OV, Karpenko EA, Inozemtseva LS, et al.

A foundational mechanistic study establishing how Semax enhances cognitive function at the molecular level. A single intranasal application of Semax (50 µg/kg) produced a 1.4-fold increase in BDNF protein levels, a 1.6-fold increase in trkB receptor phosphorylation, and a 3-fold increase in BDNF mRNA in the rat hippocampus — with treated animals showing a significant increase in conditioned learning responses. BDNF (brain-derived neurotrophic factor) is the brain’s primary growth factor for neurons and synaptic plasticity, and its upregulation is linked to improved memory, learning, and neuroprotection. This study established the BDNF/trkB pathway as the key mechanism behind Semax’s cognitive effects.

Medvedeva EV, Dmitrieva VG, Povarova OV, et al.

A genome-wide study examining how Semax protects the brain during stroke — one of its primary clinical applications in Russia. Using a rat model of focal cerebral ischemia, researchers found that Semax significantly modulated over 1,500 genes, primarily in the immune and vascular systems. Rather than acting purely on neurons, Semax enhanced the activity of immune cells (mobilizing microglia and leukocytes) and promoted vascular gene expression to support blood flow restoration. This uncovered a previously unknown mechanism for Semax’s neuroprotective effects — immunomodulation and vascular support during ischemia — explaining why it has been effective in stroke therapy beyond its cognitive-enhancing properties.

Dmitrieva VG, et al.

A follow-up transcriptome study using the more clinically relevant ischemia-reperfusion model — which better mimics what happens during and after a stroke in humans. RNA sequencing identified 394 differentially expressed genes in Semax-treated vs. saline-treated animals at 24 hours post-stroke. Semax suppressed inflammation-related gene expression while simultaneously activating neurotransmission-related genes — the precise opposite of what ischemia alone produces. This complementary action — damping harmful inflammation while restoring neural signaling — provides a compelling mechanistic explanation for Semax’s clinical effectiveness in stroke rehabilitation.

PMC Research Group

One of the most recent Semax studies, examining its potential in Alzheimer’s disease using transgenic mice that develop amyloid plaques similar to human AD pathology. Both Semax and a derivative improved cognitive function across multiple behavioral tests — including open field, novel object recognition, and Barnes maze tests. Histological analysis showed reduced amyloid plaque burden in the cortex and hippocampus of treated animals. This is significant because Semax not only improved cognition but appeared to directly reduce the pathological protein aggregation that defines Alzheimer’s disease — a meaningful advance beyond the symptomatic improvements documented in earlier studies.

Alzheimer’s Drug Discovery Foundation (ADDF) — Cognitive Vitality Program

A balanced, independent evidence review of Semax from the Alzheimer’s Drug Discovery Foundation — one of the most credible non-Russian assessments of the compound. The report acknowledges Semax’s use in Russia for stroke, encephalopathy, Parkinson’s disease, and newborns with neurological deficits. It documents a human pilot study showing improved attention and short-term memory in healthy subjects, and a clinical study in stroke patients showing increased plasma BDNF levels and improved rehabilitation timing. The report is appropriately cautious — noting that most high-quality human data remains published in Russian and that English-language clinical evidence is limited — while acknowledging the compound’s promising mechanism and safety profile.